Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

NCT00638690 is registered in ClinicalTrials.gov with Cougar Biotechnology, Inc. as lead sponsor.

NCT NCT00638690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00638690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Lead sponsor
Cougar Biotechnology, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
October 31, 2012
Enrollment
1,195 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms